Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We describe the use of a novel bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression called COPA (cancer outlier profile analysis). We demonstrate how this approach led to the identification of gene fusions of the 5 0 -untranslated region of TMPRSS2 (21q22.3), an androgen regulated gene, with the ETS transcription factor family members, either ERG (21q22.2), ETV1 (7p21.2), or ETV4(17q21). These novel gene fusions suggest a mechanism for overexpression of the ETS genes in the majority of prostate cancers identified through PSA screening. Considering the high incidence of prostate cancer and the high frequency of this gene fusion, the TMPRSS2-ETS gene fusions are the most common genetic aberration so far described in human malignancies. The clinical implications of this discovery are significant for diagnosis and potentially for the development of targeted therapy.
Microarray experiments generate copious data that can be used to identify significantly differentially expressed genes between known classes of samples. This approach can lead to the identification of molecular biomarkers. For example, AMACR (amethylacyl CoA racemase), hepsin, and fatty acid synthetase are all over expressed in prostate cancer as compared to benign prostate tissue. [1] [2] [3] Statistical significance for biomarkers is demonstrated by comparing the mean expression of one class to another. For example in Figure 1 (left, biomarkers profile), AMACR in prostate cancer (class 2, red) is significantly over expressed as compared to the reference class-benign prostate tissue (class 1, blue). These results are visually appreciated by ordering the expression of AMACR by class.
The difference in the mean AMACR expression between the two groups is statistically significant although there is some expression in benign tissues that is at a similar level to some prostate cancer samples. In order to rank the best biomarkers for a specific class, one can compare the results of multiple micorarray experiments in a meta-analysis approach. In a meta-analysis of four cDNA expression array data sets, AMACR was one of the genes most consistently over expressed in prostate cancer. 4 This meta-analysis approach has lead to the development of the publicly available compendium of expression array data called Oncomine (www. oncomine.org) that allows researchers to investigate over 300 expression array data sets. 5 However, one limitation to this standard biomarker analysis is how does it deal with genes significantly differentially expressed in only a subset of the tumors?
Tumor cells thrive by developing a growth advantage over neighboring benign cells through a variety of genetic and epigenetic alterations. Overexpression of oncogenes favors this growth advantage and can occur through gene copy number amplification, activating mutations or by constitutive promoter activation. Oncogenes such as her-2-neu or EGFR are examples where overexpression is observed in only a subset of tumors from patients with breast or lung cancer, respectively. Thus, the expression array profile of an oncogene, may look very different when compared to AMACR. In a recent study from our group, a simple approach was developed to identify oncogene profiles that can be characterized by overexpression of a small subset of biologically important outlier cases.
The method called cancer outlier profile analysis (COPA) was developed based on the idea that evaluating variance in a data set using the median instead of the mean would maintain the peaks of outliers. COPA has three steps. First, gene expression values are median centered, setting each gene's median expression value to zero. Second, the median absolute deviation (MAD) is calculated and scaled to 1 by dividing each gene expression value by its MAD ( Figure 1 ). This approach was used instead of centering data around the mean because it has less effect on the tails or outliers. Third, the 75th, 90th, and 95th percentiles of the transformed expression values are tabulated for each gene and then genes are rank-ordered by their percentile scores, leading to a prioritized list of outlier profiles.
By applying COPA, 132 gene expression data sets representing 10 486 microarray experiments were interrogated for outlier genes. 6 Examples of known genes that are over expressed in a subset of a particular tumor type were identified such as the oncogene her-2-neu and E-Cadherin (CDH1) (see Table 1 ). Interestingly, genes such as RUNX1T1 (ETO) and PBX1 also scored high on COPA. These two genes are known to be associated with the AML-ETO and E2A-PBX1 gene translocations in acute myeloid leukemia and acute lymphoblastic leukemia, respectively. Both of these translocations only occur in a subset of the cases (ie, outlier cases). Two genes consistently scored high in prostate cancer microarray experiments, ERG (Figure 1, right) and ETV1. Both of these genes are members of the ETS family of transcription factors. They were over expressed in the majority (50-70%) of prostate cancers and were mutually exclusive across several independent gene expression data sets, suggesting that they may be functionally redundant in prostate cancer development. 6 As the ETS family of transcription factors has previously been seen in the genomic translocation of the Ewing's family tumors, AML and other rare tumors, the possibility that they were part of a translocation in prostate cancer was explored. When the ERG cDNA transcript was evaluated exon by exon, overexpression was seen at the distal ( mechanism for overexpression of the ETS genes in prostate cancer (Figure 2) . Thus, the identification of these gene fusions between the prostate-specific, strongly androgenregulated gene TMPRSS2 (21q22.3) to ERG, ETV1, or ETV4 was a surprising discovery. Using other methods to validate these findings (ie, RT-PCR and fluorescence in situ hybridization (FISH)) in human prostate cancer samples, the TMPRSS2:ETS gene fusions are seen in up to 80% of hospital-based clinical cohorts. TMPRSS2:ETS gene fusions have been detected in approximately 20% of the precursor lesion high-grade prostatic intraepithelial neoplasia (PIN) but not prostatic atrophy (PIA) (unpublished observations). As TMPRSS2 is regulated by androgens, even in the setting of hormone ablation therapy for metastatic prostate cancer, low levels of androgen may still be sufficient to drive ETS overexpression.
The TMPRSS2:ETS gene fusion appears to be one of the earliest events involving prostate cancer invasion and leads to the over expression of the fused ETS gene in an androgen-regulated manner. The finding have now been confirmed by other groups. 21, 22 There is still much to be learned about this common prostate cancer gene fusion. Although we have recently described the common intronic deletion on chromosome 21 associated with the TMPRSS2:ERG gene fusion, 23 The DNA breakpoint(s) have not yet been identified but would help in the development of diagnostic tools for prostate cancer. The exact frequency of the TMPRSS2:ETS fusion still needs to be determined in population-based studies. The high percentage of TMPRSS2:ERG fusion prostate cancers suggests that ERG may be the most common fusion partner. The hospital-based studies to date suggest that at least 50% of prostate cancers harbor the TMPRSS2:ERG gene fusion. With the recent identification of a third molecular subtype (TMPRSS2:ETV4), 20 one can anticipate finding other translocation partners such as FLI1 based on expression array data. This would be similar to observation in the Ewing's family tumors, where approximately 85% of tumors harbor a tumor-associated t(11;22)(q24;q12) rearrangement 24 Finally, the identification of the TMPRSS2:ETS gene fusion in prostate cancer suggests that distinct molecular subtypes may further define risk for disease progression.
The discovery of the common TMPRSS2:ETS gene fusions in prostate cancer using COPA suggest that other translocations may be identified in common epithelial tumors. The combination of an organ specific promoter such as TMPRSS2 for prostate cancer fused to an oncogene may also be a common theme in carcinogenesis. COPA has now begun a new search for targetable fusion products. Perhaps, leading to rational drug development similar to the development of imatinib (STI571, Gleevec) therapy for CML.
